Patents Assigned to Adherex Technologies, Inc.
  • Patent number: 8658618
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: February 25, 2014
    Assignee: Adherex Technologies, Inc.
    Inventor: Thomas Spector
  • Patent number: 8318756
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 27, 2012
    Assignee: Adherex Technologies, Inc.
    Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
  • Patent number: 7481999
    Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: January 27, 2009
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, Barbara J. Gour, James Matthew Symonds, Stephen Byers
  • Patent number: 7476509
    Abstract: Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and/or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: January 13, 2009
    Assignee: Adherex Technologies Inc.
    Inventors: Orest W Blaschuk, Stephanie D Michaud
  • Patent number: 7456153
    Abstract: Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: November 25, 2008
    Assignee: Adherex Technologies Inc.
    Inventors: Orest W. Blaschuk, Stephanie D. Michaud
  • Patent number: 7446120
    Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: November 4, 2008
    Assignee: Adherex Technologies, Inc.
    Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie D. Michaud, Shoameng Wang, Zenjian Hu
  • Patent number: 7268115
    Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: September 11, 2007
    Assignee: Adherex Technologies, Inc.
    Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie Denise Michaud, Shaomeng Wang, Zenjian Hu
  • Patent number: 7122623
    Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: October 17, 2006
    Assignee: Adherex Technologies, Inc.
    Inventor: Orest W Blaschuk
  • Publication number: 20060183884
    Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: August 17, 2006
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, Barbara Gour, Riaz Farookhi, Anmar Ali, Sarah George
  • Publication number: 20060148753
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Application
    Filed: December 5, 2005
    Publication date: July 6, 2006
    Applicant: Adherex Technologies, Inc.
    Inventors: Thomas Spector, William Peters, Donald Kufe, Brian Huber
  • Patent number: 6962969
    Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: November 8, 2005
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Publication number: 20050222037
    Abstract: Compositions and methods for modulating VE-cadherin-mediated functions are provided. The compositions and methods employ VE-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to a VE-cadherin cell adhesion recognition sequence; (b) a non-peptide mimetic of a VE-cadherin cell adhesion recognition sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a VE-cadherin cell adhesion recognition sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a VE-cadherin cell adhesion recognition sequence or analogue thereof.
    Type: Application
    Filed: December 3, 2004
    Publication date: October 6, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
  • Publication number: 20050215482
    Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.
    Type: Application
    Filed: December 3, 2004
    Publication date: September 29, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
  • Publication number: 20050203025
    Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: December 3, 2004
    Publication date: September 15, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
  • Publication number: 20050163786
    Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Application
    Filed: October 1, 2004
    Publication date: July 28, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Patrick Doherty, Orest Blaschuk, Barbara Gour
  • Publication number: 20050129676
    Abstract: Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.
    Type: Application
    Filed: November 14, 2003
    Publication date: June 16, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, Stephanie Michaud
  • Publication number: 20050037973
    Abstract: Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used for cancer therapy or to increase immune cell infiltration into tumors. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Application
    Filed: July 6, 2004
    Publication date: February 17, 2005
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest Blaschuk, James Symonds, Barbara Gour, J. Alexander
  • Publication number: 20040254099
    Abstract: Modulating agents for inhibiting &bgr;-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating &bgr;-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.
    Type: Application
    Filed: October 14, 2003
    Publication date: December 16, 2004
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, Stephen Byers, Barbara J. Gour
  • Patent number: 6830894
    Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 14, 2004
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Publication number: 20040248220
    Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.
    Type: Application
    Filed: January 16, 2004
    Publication date: December 9, 2004
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour